APA (7th ed.) Citation

Estrella-Porter, P., Correcher-Martínez, E., Orrico-Sánchez, A., & Carreras, J. J. Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign. MDPI AG.

Chicago Style (17th ed.) Citation

Estrella-Porter, Pablo, Elisa Correcher-Martínez, Alejandro Orrico-Sánchez, and Juan José Carreras. Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign. MDPI AG.

MLA (9th ed.) Citation

Estrella-Porter, Pablo, et al. Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain’s 2023–2024 RSV Immunisation Campaign. MDPI AG.